Maintenance therapy study for stable metastatic pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, DZ-002, as maintenance therapy for people with metastatic pancreatic cancer whose disease has not worsened after at least 4 months of first-line chemotherapy. The goal is to help keep the cancer under control with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic pancreatic cancer that has spread to other parts of the body.
- You completed at least 4 months of first-line chemotherapy and your latest CT scan shows your cancer is stable or better.
- You are 18 years or older.
- You are in good enough health to perform daily activities (ECOG score 0 or 1).
- Your heart, lung, kidney, and liver functions are within safe limits as shown by recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.